PALI

Palisade Bio Inc

1.41

Oct 14 • 10:34 AM ET -0.05 (-3.42%)

Healthcare Biotechnology USA Micro NASD

Oct 12, 8:10 AMPalisade Bio unveils new Phase 1a/1b data for oral PDE4 prodrug PALI-2108 in UC and fibrostenotic Crohn’s disease at ACG 2026

Peers: EDIT AVXL ACIU ARTV PRLD TARA NGEN VYGR RIGL RZLT

| Held by: IWM VXF IWN VTWO IWC SURI ITOT VFMO IWO AVSC

Scroll to Statements

Index	RUT
Market Cap	246.58M
Enterprise Value	121.41M
Income	-31.94M
Sales	0.50M
Book/sh	0.70
Cash/sh	0.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Dec 20, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	493.16
P/B	2.02
P/C	1.97
P/FCF	-
EV/EBITDA	-
EV/Sales	242.82
Quick Ratio	24.25
Current Ratio	24.25
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.54
EPS next Y	-0.28
EPS next Q	-0.06
EPS this Y	25.33%
EPS next Y	-25.89%
EPS next 5Y	-3.67%
EPS past 3/5Y	89.33% 88.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	91.31%
Sales Y/Y TTM	-
EPS Q/Q	91.38%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	4.21% -

Insider Own	7.77%
Insider Trans	-0.39%
Inst Own	96.93%
Inst Trans	7.99%
ROA	-47.68%
ROE	-51.37%
ROIC	-26.24%
Gross Margin	-0.40%
Oper. Margin	-7069.80%
Profit Margin	-6388.20%
SMA20	-6.76%
SMA50	-23.19%
SMA200	-25.47%
Trades

Shs Outstand	173.60M
Shs Float	160.72M
Short Float	19.30%
Short Ratio	12.43
Short Interest	31.02M
52W High	2.86 -50.44%
52W Low	1.32 7.19%
Volatility	6.58% 7.55%
ATR (14)	0.11
RSI (14)	37.64
Beta	1.63
Rel Volume	0.83
Avg Volume	2.49M
Volume	432,153

Perf Week	-4.40%
Perf Month	-29.78%
Perf Quarter	-25.14%
Perf Half Y	-39.53%
Perf YTD	-39.79%
Perf Year	-23.52%
Perf 3Y	-82.93%
Perf 5Y	-99.93%
Perf 10Y	-100.00%
Recom	1.09
Target Price	10.00
Prev Close	1.47
Price	1.41
Change %	-3.42%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-26	Initiated	Raymond James	Outperform	$6
Jul-23-26	Initiated	Oppenheimer	Outperform	$8
Apr-09-26	Initiated	Wolfe Research	Outperform	$7
Mar-26-26	Initiated	H.C. Wainwright	Buy	$7
Feb-25-26	Initiated	Stifel	Buy	$5
Jan-09-26	Initiated	B. Riley Securities	Buy	$7
Dec-29-25	Initiated	Piper Sandler	Overweight	$25

Oct-12-26 08:05AM	Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn's Disease at ACG 2026 (GlobeNewswire)
Sep-28-26 08:50AM	Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 (GlobeNewswire)
Sep-23-26 08:45AM	Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance (GlobeNewswire) -5.33%
Sep-22-26 08:35AM	Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD (GlobeNewswire)
Sep-21-26 09:00AM	Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +6.29%
09:00AM	Loading…
Sep-03-26 09:00AM	Palisade Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-26 04:20PM	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development (GlobeNewswire)
Jul-10-26 09:00AM	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum (GlobeNewswire)
Jun-29-26 01:49PM	PALI Stock Heads For Best Day In Seven Months Whats Driving Todays Rally? (Stocktwits) +17.99%
08:30AM	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis (GlobeNewswire)
Jun-11-26 08:45AM	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors (GlobeNewswire) +5.95%
Jun-09-26 08:45AM	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium (GlobeNewswire)
May-27-26 09:00AM	Palisade Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 04:15PM	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 (GlobeNewswire)
May-05-26 08:30AM	Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis (GlobeNewswire) -7.51%
08:50AM	Loading…
Apr-16-26 08:50AM	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 (GlobeNewswire)
Apr-08-26 09:00AM	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference (GlobeNewswire)
Mar-30-26 04:01PM	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease (GlobeNewswire) -11.00%
Mar-02-26 09:00AM	Palisade Bio Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 06:30AM	Palisade Bio Details PALI-2108 UC, Crohns Plans and Cash Runway Into 2029 at Oppenheimer Conference (MarketBeat)
Feb-23-26 08:40AM	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 (GlobeNewswire)
Feb-17-26 08:45AM	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board (GlobeNewswire)
Feb-09-26 09:00AM	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire)
Feb-05-26 08:45AM	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.06%
Jan-29-26 08:45AM	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board (GlobeNewswire)
Jan-16-26 08:30AM	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences (GlobeNewswire) -5.14%
Jan-07-26 08:15AM	Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 (GlobeNewswire) +5.21%
Dec-30-25 08:35AM	Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +15.35%
Dec-25-25 10:37AM	Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results (Insider Monkey)
12:00PM	Loading…
Dec-19-25 12:00PM	Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know (Zacks) +9.58%
Dec-02-25 08:45AM	Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development (GlobeNewswire)
Nov-25-25 08:45AM	Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) -5.70%
Nov-10-25 09:55AM	Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher (Zacks) +5.36%
Nov-06-25 12:00PM	All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy (Zacks)
Oct-28-25 08:45AM	Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations (GlobeNewswire) +11.45%
Oct-20-25 08:45AM	Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire) +6.90%
Oct-13-25 08:45AM	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 (GlobeNewswire) -7.50%
Oct-09-25 05:00PM	Palisade Bio Announces Cancellation of Special Meeting of Stockholders (GlobeNewswire)
Oct-02-25 04:05PM	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option (GlobeNewswire) +29.77% -5.88%
Oct-01-25 09:20AM	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +52.38%
Sep-26-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +16.20%
Sep-18-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Sep-17-25 09:00AM	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data (GlobeNewswire)
Sep-05-25 08:45AM	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire)
Aug-25-25 09:00AM	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 (GlobeNewswire) -8.46%
Aug-11-25 07:04AM	Palisade reports outcomes from Phase Ib ulcerative colitis study (Clinical Trials Arena) -6.34%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.16%
09:15AM	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 (GlobeNewswire)
Jul-31-25 08:45AM	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China (GlobeNewswire)
Jul-30-25 06:30AM	PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR (PR Newswire)
Jul-23-25 08:00PM	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million (GlobeNewswire) +41.86% -9.02%
Jul-22-25 08:45AM	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire) -9.20%
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-09-25 08:45AM	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors (GlobeNewswire) +5.41%
May-27-25 08:30AM	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis (GlobeNewswire)
May-06-25 08:30AM	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases (GlobeNewswire) +6.07%
May-01-25 08:30AM	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit (GlobeNewswire)
Apr-09-25 08:30AM	Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire)
Mar-14-25 08:30AM	Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM	Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM	Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM	Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM	Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM	Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM	Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM	Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
Jan-16-25 08:00AM	Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Dec-17-24 08:30AM	Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board (GlobeNewswire)
Dec-13-24 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-21-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models (GlobeNewswire) -7.52%
May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.

CEOMr. J. D. Finley

Ph.D.Dr. Mitchell Lawrence Jones M.D.

Senior VP of Corporate Development & Investor RelationsMr. Ramesh C. Donthamsetty C.F.A.

Head of Translational Science & MedicineDr. Joerg Heyer Ph.D.

VP & Head of Clinical DevelopmentDr. James Izanec M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Donald Allen	Director	Oct 02 '26	Buy	1.46	10,000	14,600	1,590,294	Oct 05 05:20 PM
Williams Donald Allen	Director	Oct 01 '26	Buy	1.42	10,000	14,200	1,580,294	Oct 05 05:20 PM
Baltera Robert Jr.	Director	Jul 09 '26	Buy	1.96	25,000	48,900	461,904	Jul 10 06:14 PM
Baltera Robert Jr.	Director	Jul 08 '26	Buy	1.99	20,000	39,798	436,904	Jul 10 06:14 PM
Baltera Robert Jr.	Director	Jul 07 '26	Buy	2.03	30,000	61,044	416,904	Jul 08 06:56 PM
Baltera Robert Jr.	Director	Jul 06 '26	Buy	2.05	20,000	41,040	386,904	Jul 08 06:56 PM
Jones Mitchell Lawrence	Chief Medical Officer	Jul 07 '26	Sale	2.05	51,880	106,536	94,009	Jul 08 06:52 PM
Finley John David	CEO, CFO	Jul 07 '26	Option Exercise	0.70	133	93	217,688	Jul 08 06:49 PM
Finley John David	CEO, CFO	Jul 07 '26	Sale	2.07	146,798	303,343	217,555	Jul 08 06:49 PM
Jones Mitchell Lawrence	Officer	Jul 07 '26	Proposed Sale	2.04	53,000	108,120		Jul 07 05:18 PM
Finley John David	Officer	Jul 07 '26	Proposed Sale	2.07	146,798	303,343		Jul 07 04:59 PM
Baltera Robert Jr.	Director	Jul 01 '26	Buy	1.98	20,000	39,600	356,904	Jul 06 07:48 PM
Baltera Robert Jr.	Director	Jul 02 '26	Buy	1.98	10,000	19,800	366,904	Jul 06 07:48 PM
Jones Mitchell Lawrence	Chief Medical Officer	Feb 12 '26	Sale	1.75	1,989	3,481	13,263	Feb 13 08:10 PM
Finley John David	CEO, CFO	Feb 12 '26	Sale	1.75	3,896	6,818	27,353	Feb 13 08:07 PM
Williams Donald Allen	Director	Jan 16 '26	Buy	1.67	5,000	8,356	10,728	Jan 21 04:05 PM
Williams Donald Allen	Director	Jan 09 '26	Buy	1.88	5,000	9,400	5,728	Jan 13 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your Finviz experience